AwardsCertificate of Merit
ParticipantsTamara Lundeen, MD, Tucson, AZ (Presenter) Nothing to Disclose
Phillip Kuo, MD,PhD, Tucson, AZ (Abstract Co-Author) Author, MD Training at Home; Research Grant, Astellas Group; Consultant, Endocyte, Inc; Consultant, General Electric Company; Education Grant, General Electric Company; Speakers Bureau, Eli Lilly and Company; Consultant, inviCRO, LLC; Consultant, Imaging Endpoints; Consultant, Progenics Pharmaceuticals, Inc
Matthew Covington, MD, St. Louis, MO (Abstract Co-Author) Nothing to Disclose
Naghmehossadat Eshghi, MD, PhD, Tucson, AZ (Abstract Co-Author) Nothing to Disclose
John Seibyl, MD, New Haven, CT (Abstract Co-Author) Researcher, inviCRO, LLC
1. Discuss the appropriate use criteria for amyloid PET imaging. 2. Explain the algorithmic approach to scan interpretation. 3. Introduce the common amyloid PET imaging signs and artifacts.
TABLE OF CONTENTS/OUTLINEIntroduction to amyloid PET imaging. -Discuss radiopharmaceutical properties of the three FDA approved PET amyloid agents - Review the current existing appropriate use criteria for amyloid PET imaging - Review manufacture-specific recommendations for amyloid PET interpretation. Present a detailed algorithmic approach to amyloid PET scan interpretation. - Discuss a novel region-based search pattern to aid with amyloid PET interpretation - Provide examples of normal and abnormal amyloid PET scans. Provide an atlas of regional amyloid PET imaging signs in normal and abnormal brains. - Example amyloid PET scans with MRI correlation of the temporal/occipital, frontal, parietal and striatal regions. Illustrate common imaging artifacts with example images. Conclusion and summary table with the composite atlas of imaging signs.